| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 5.018 | 5.121 | 3.804 | 6.207 | 9.300 | 8.915 | 6.755 |
| Total Income - EUR | - | - | - | 5.018 | 5.121 | 3.804 | 6.207 | 9.300 | 8.915 | 6.755 |
| Total Expenses - EUR | - | - | - | 1.607 | 416 | 505 | 1.456 | 308 | 1.416 | 936 |
| Gross Profit/Loss - EUR | - | - | - | 3.411 | 4.704 | 3.298 | 4.750 | 8.992 | 7.500 | 5.819 |
| Net Profit/Loss - EUR | - | - | - | 3.260 | 4.551 | 3.185 | 4.586 | 8.715 | 6.324 | 4.904 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Medleudoc S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 906 | 617 | 290 | 0 | 505 | 302 |
| Current Assets | - | - | - | 3.336 | 6.911 | 10.226 | 14.899 | 17.893 | 7.800 | 13.124 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 183 | 0 | 77 | 419 | 278 | 338 | 201 |
| Cash | - | - | - | 3.153 | 6.911 | 10.149 | 14.480 | 17.615 | 7.462 | 12.923 |
| Shareholders Funds | - | - | - | 3.303 | 7.790 | 10.827 | 15.173 | 17.852 | 8.353 | 4.953 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 33 | 27 | 16 | 16 | 41 | 250 | 8.473 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Medleudoc S.r.l.